SEC Form	n 4
----------	-----

Instruction 1(b)

**Common Shares** 

## FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

See

See

Footnote<sup>(13)</sup>

Footnote<sup>(14)</sup>

I

38,772

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading Symbol 5. Relationship of Reporting Person(s) to Issuer 1. Name and Address of Reporting Person (Check all applicable) <u>CRISPR Therapeutics AG</u> [ CRSP ] **Bolzon Bradley J PhD** X Director 10% Owner Officer (give title Other (specify 3. Date of Earliest Transaction (Month/Day/Year) (Middle) below) below) (Last) (First) 12/16/2020 C/O CRISPR THERAPEUTICS, INC. 610 MAIN STREET 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) (Street) X Form filed by One Reporting Person CAMBRIDGE MA 02139 Form filed by More than One Reporting Person

## (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 2. Transaction Date 2A. Deemed Execution Date, 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 6. Ownership Form: Direct 1. Title of Security (Instr. 3) 5. Amount of 7. Nature of Transaction Securities Beneficially Indirect Beneficial (Month/Day/Year) (D) or if any Code (Instr. Owned Following (Month/Day/Year) 8) Indirect (I) Ownership (Instr. 4) (Instr. 4) Reported Transaction(s) (Instr. 3 and 4) (A) or (D) v Price Code Amount **S**<sup>(1)</sup> \$147.002(2) 6,734 D Common Shares 12/16/2020 914 D See **S**<sup>(1)</sup> 878(3) \$147.002<sup>(2)</sup> Common Shares 12/16/2020 D 346,308 I Footnote<sup>(4)</sup> **S**<sup>(1)</sup> \$148.2811(5) Common Shares 12/16/2020 2,679 D 4,055 D See **S**<sup>(1)</sup> Common Shares 12/16/2020 2,576(3) D \$148.2811(5) 343,732 I Footnote<sup>(4)</sup> **S**<sup>(1)</sup> Common Shares 12/16/2020 2,091 D \$149.1222(6) 1,964 D See **S**<sup>(1)</sup> 2,009(3) \$149.1222(6) Common Shares 12/16/2020 D 341,723 I Footnote<sup>(4)</sup> **Common Shares** 12/16/2020 **S**<sup>(1)</sup> 995 D \$150.1432(7) 969 D See **S**<sup>(1)</sup> 958(3) **Common Shares** 12/16/2020 D \$150.1432(7) 340,765 I Footnote<sup>(4)</sup> **S**<sup>(1)</sup> D **Common Shares** 12/16/2020 969 D \$151.0474(8) 0 See **S**<sup>(1)</sup> **931**<sup>(3)</sup> **Common Shares** \$151.0474(8) I 12/16/2020 D 339.834 Footnote<sup>(4)</sup> See **Common Shares** 1,336,088 I Footnote<sup>(9)</sup> See Common Shares 7.922 I Footnote<sup>(10)</sup> See **Common Shares** 1,192,139 I Footnote<sup>(11)</sup> See **Common Shares** 34,977 I Footnote<sup>(12)</sup>

 Common Shares
 90,730
 I

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

 1. Title of
 2.
 3. Transaction
 3A. Deemed
 4.
 5. Number
 6. Date Exercisable and
 7. Title and
 8. Price of
 9. Number of
 10.

	(0.3., pare, ours, options, options, options)											
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	Expiration Date	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	

		Tal	ble II - Derivat (e.g., pι					convertib	or Bernerities	1.	d		
1. Title of	2. Conversion	3. Transaction	3A. Deemed Execution Date.	Code V		Num(Diệr	Date ExDetis Elater Expiration E		of 7itītētle Salnalres Amount of	8. Price of Derivative		10. Ownership	11. Nature
	noorfERespons	e(\$/tonth/Day/Year)		Code (Ins	str. De	erivative curities cach of t	(Month/Day	Year)	Securities	Security (Instr. 5) gement, LLC	Securities Beneficially	Form: Direct (D)	Beneficial Ownership . (Instr. 4)
provide to th within the ra	re <b>Socurity</b> Col le Issuer, any se inges set forth in	umn 4 is a weighted a curity holder of the Is n this footnote (2) to	average price. These s ssuer or the staff of th this Form 4.	ecurities v e Securitie	vere sq(A es ExclQi of - (In	)iormultip spoSedni (D) str 3 4	ple transactions mission, upon i	at prices rang equest, full int	in <b>§écuritýl(46stř.</b> fo <b>shanid 4)</b> regardin -	g the number	clificillowling Repo of Reported: sold : Transaction(s)	rti <b>(i)g(Rustr</b> or <b>4)</b> u	ndertakes to
4. These sec	urities are held	of record by VVM L	LC, for the benefit of LC. The Reporting Pe g Person disclaims be	rson is a n	nanaging	member	of VVM LLC	and the Repor	ting Person may be	e deemed to in	directly beneficia	lly own the sec	curities
provide to th	e İssuer, any se		average price. These s ssuer or the staff of th this Form 4.										
provide to th	e Issuer, any se	umn 4 is a weighted a curity holder of the Is n this footnote (6) to	average price. These s ssuer or the staff of th this Form 4.	ecurities v e Securitie Code	vere sold s Exchai	in multip nge Comi ( <b>D</b> )	ole transactions mission upon i Exercisable	at prices rang eq <b>Expiration</b> Date	ing from <b>Number</b> formation <b>of</b> <b>Title Shares</b>	to \$149.60, in g the number	clusive. The Repo of securities sold	rting Person u at each separat	ndertakes to e price
provide to th	ie Îssuer, any se		average price. These s ssuer or the staff of th this Form 4.										
provide to th	ie Îssuer, any se		average price. These s ssuer or the staff of th this Form 4.										
investment p	ower over the s directly benefic	securities held by VV	Venture Capital IV, L C IV and as a result r ies through his interest	nay be dee	med to h	ave benet	ficial ownershi	p over such se	curities. The Repo	rting Person is	s a managing direc	ctor of VV IV	and may be
held by VSF	IV and as a res	sult may be deemed to	t Side Fund IV, L.P. (' o have beneficial own	ership ove	r such se	curities.	The Reporting	Person is a ma	naging director of	VV IV and m	ay be deemed to i		

the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. 11. These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.

12. These securities are held of record by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.

13. These securities are held of record by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.

14. These securities are held of record by Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the securities through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any.

Remarks:

/s/ Robin L. Praeger, attorneyin-fact for Bradley Bolzon 12/18/2020

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.